Back to Search
Start Over
Management of factor VIII inhibitors.
- Source :
-
Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2006; Vol. 19 (1), pp. 51-66. - Publication Year :
- 2006
-
Abstract
- The development of inhibitory alloantibodies to factor VIII is arguably one of the most severe and important complications of clotting factor concentrate exposure in haemophilia A. The development of an inhibitor compromises the ability to effectively manage haemorrhage, resulting in a greater rate of disability, complications and costs of therapy. This chapter briefly reviews the epidemiology, immunobiology, and laboratory evaluation of inhibitors. It discusses the therapeutic approach and management of inhibitors in various clinical settings and also focuses on inhibitor eradication practices (immune tolerance) and newer experimental strategies with potential clinical application for inhibitor prevention.
- Subjects :
- Autoantibodies pharmacology
Blood Coagulation Factor Inhibitors pharmacology
Blood Coagulation Factors therapeutic use
Factor VIII antagonists & inhibitors
Factor VIII therapeutic use
Hemophilia A drug therapy
Hemophilia A epidemiology
Hemorrhage epidemiology
Humans
Recombinant Proteins therapeutic use
Autoantibodies immunology
Blood Coagulation Factor Inhibitors immunology
Factor VIII immunology
Hemophilia A immunology
Hemorrhage immunology
Hemorrhage therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1521-6926
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Best practice & research. Clinical haematology
- Publication Type :
- Academic Journal
- Accession number :
- 16377541
- Full Text :
- https://doi.org/10.1016/j.beha.2005.03.002